Expert Review - Nivolumab as Second Line Therapy
SIU Academy®. Ingels A. 02/29/16; 128207
Topic: Molecular/biological therapies
Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}